Background: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. Results: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. Conclusions: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive.

Veenstra, E., Ruiter, S., de Haas, R., de Jong, K., Erba, P., Dierckx, R., et al. (2023). A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making. EJNMMI RESEARCH, 13(1) [10.1186/s13550-023-01024-y].

A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making

Erba, Paola A;
2023

Abstract

Background: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. Results: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. Conclusions: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive.
Articolo in rivista - Articolo scientifico
Clinical decision making; Dual-tracer PET/CT imaging; Hepatocellular carcinoma; [11C]CH; [18F]FDG;
English
29-ago-2023
2023
13
1
77
open
Veenstra, E., Ruiter, S., de Haas, R., de Jong, K., Erba, P., Dierckx, R., et al. (2023). A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making. EJNMMI RESEARCH, 13(1) [10.1186/s13550-023-01024-y].
File in questo prodotto:
File Dimensione Formato  
Veenstra-2023-EJNMMI Res-AAM.pdf

accesso aperto

Descrizione: Original Research Article
Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Licenza: Creative Commons
Dimensione 377.53 kB
Formato Adobe PDF
377.53 kB Adobe PDF Visualizza/Apri
Veenstra-2023-EJNMMI Res-VoR.pdf

accesso aperto

Descrizione: Original Research Article
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/436140
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact